STOCK TITAN
  1. Home
  2. News
  3. ARAY

Accuray Inc - ARAY STOCK NEWS

Welcome to our dedicated news page for Accuray (Ticker: ARAY), a resource for investors and traders seeking the latest updates and insights on Accuray.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Accuray's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Accuray's position in the market.

News
Accuray Expands Global Training Center Network With Opening of New Facility in Genolier, Switzerland
Rhea-AI Summary
Accuray Incorporated (NASDAQ: ARAY) expands its global training center network by opening a new facility in Genolier, Switzerland. The center aims to advance patient care through education on the Accuray CyberKnife® and Radixact® Systems. The facility offers hands-on simulation, seminars, and workshops for medical professionals involved in radiotherapy and radiosurgery. The partnership with Genolier Innovation Hub enhances access to high-quality training and innovative techniques.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Accuray to Report Third Quarter Fiscal 2024 Financial Results on May 1, 2024
Rhea-AI Summary
Accuray Incorporated (NASDAQ: ARAY) will report financial results for the third quarter of fiscal year 2024 on May 1, 2024. The conference call will be hosted by company management at 1:30 p.m. PT/4:30 p.m. ET. Investors can access the call through dial-in numbers or a live webcast on the company's Investor Relations website. A replay will be available for one week after the call.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
-
News
New Data from Two Clinical Studies Indicate High-Risk and Recurrent Prostate Cancers Can be Effectively Treated in 5 Days Using the Accuray CyberKnife® System
Rhea-AI Summary
Accuray Incorporated (NASDAQ: ARAY) presented new data at the 2024 Radiosurgery Society Meeting supporting the use of the CyberKnife System in treating high-risk and recurrent prostate cancer. The system's precision with stereotactic body radiation therapy (SBRT) offers effective treatment in 4-5 sessions compared to traditional therapy. The data highlighted favorable outcomes, low toxicities, and the system's ability to track and correct for prostate movement during treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.44%
Tags
clinical trial
News
Accuray Incorporated to Speak at 36th Annual Roth Conference
Rhea-AI Summary
Accuray Incorporated (ARAY) will participate in the 36th Annual Roth Conference with a fireside chat on March 18, 2024. The event will be live webcasted and available for replay on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.18%
Tags
conferences
-
News
Accuray Incorporated to Speak at Oppenheimer 34th Annual Healthcare MedTech & Services Conference
Rhea-AI Summary
Accuray Incorporated (ARAY) will participate in the Oppenheimer 34th Annual Healthcare MedTech & Services Conference on March 12-13, 2024. The management team will engage in a fireside chat on March 12, 2024, at 7:00am PST / 10:00am EST. Investors can access the live webcast on the Accuray website with a replay available post-event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.69%
Tags
conferences
-
News
Quebec Cancer Center is First in Canada to Treat Cancer Patients Using the Accuray Radixact® System
Rhea-AI Summary
Accuray Incorporated (NASDAQ: ARAY) partners with Montérégie Integrated Cancer Center to introduce Radixact System for cancer treatment in Quebec. The system includes ClearRT™ and Synchrony® technologies to enhance treatment outcomes and minimize side effects. The center aims to set a new standard in precision and accuracy for radiation therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.14%
Tags
none
News
Accuray to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
Rhea-AI Summary
Accuray Incorporated (NASDAQ: ARAY) is set to participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 13, 2024. The event is exclusive to BTIG clients, offering the opportunity for one-on-one meetings with management.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.4%
Tags
conferences
-
News
Accuray Reports Fiscal 2024 Second Quarter Financial Results
Rhea-AI Summary
Accuray Incorporated (NASDAQ: ARAY) reported a 19% increase in gross orders, 8% service revenue expansion, and confirmed FY24 guidance. Net revenue for the second quarter of fiscal 2024 was $107.2 million, a 3% sequential increase and a 7% decrease from the same period in the prior fiscal year. GAAP net loss was $9.6 million, compared to $1.9 million in the prior fiscal year. Adjusted EBITDA was $2.0 million, compared to $8.5 million in the same period in the prior fiscal year. The company also reported a 6% increase in gross orders for the first six months of fiscal 2024 and reaffirmed guidance for fiscal year 2024, expecting total revenue in the range of $460 million to $470 million, representing a year-over-year growth range of 3 to 5 percent.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.16%
Tags
earnings
-
News
Providence Swedish Radiosurgery Center in Seattle Invests in Second Accuray CyberKnife® System, a Robotic Delivery Device That Makes Extremely Precise Radiation Treatments Possible in 1-5 Sessions
Rhea-AI Summary
Accuray Incorporated (NASDAQ: ARAY) announced that the Providence Swedish Radiosurgery Center in Seattle, Washington is enhancing its cancer treatment capabilities with the purchase of the latest generation CyberKnife S7 System, the hospital's second CyberKnife radiation delivery device purchase. The precision and accuracy enabled by the system's robotic design will also make it an ideal choice for the treatment of neurologic disorders. The new system will enable the medical team to deliver gold standard stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT) treatments faster than with previous models, expanding access to an effective and convenient option to more patients. The CyberKnife S7 System is a non-invasive radiation therapy device that was built from the ground-up to provide clinicians with the speed they need for operational efficiency without sacrificing the precision and accuracy required for stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.36%
Tags
none
News
Accuray to Report Second Quarter Fiscal 2024 Financial Results on January 31, 2024
Rhea-AI Summary
Accuray Incorporated (NASDAQ: ARAY) will report financial results for the second quarter of fiscal year 2024, ended December 31, 2023, during a conference call on January 31, 2024. The conference call will be hosted by company management and a live webcast will be available. Investors can access the webcast replay from the Investor Relations section of the company's website. The dial-in numbers for the conference call and the replay numbers are provided for both USA and international participants.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
Stock ARAY logo
Accuray Inc

Nasdaq:ARAY

ARAY Rankings

#3673 Ranked by Market Cap
#726 Ranked by Stock Gains
N/A Ranked by Dividends

ARAY Stock Data

221.15M
88.53M
3.58%
66.36%
5.31%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
Sunnyvale

About ARAY

accuray incorporated (nasdaq: aray) is a radiation oncology company that develops, manufactures and sells precise, innovative tumor treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. the company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. for more information, please visit www.accuray.com. for career opportunities, please visit http://www.accuray.com/careers.